Myriad outlines $780M-$790M 2026 revenue outlook after $210M Prenatal Health divestiture
FROM THE WIRE · SEEKINGALPHA.COM
Earnings Call Insights: Myriad Genetics (MYGN) Q3 2026 MANAGEMENT VIEW * “We understand the key challenges that we've been facing, continued softness in our Prenatal Health business, reimbursement pressure on HCT and financial stability, and we have been taking decisive actions…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralRevenue guidance and a business divestiture are relevant for the stock's outlook.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Myriad signed a definitive agreement to sell Prenatal Health to Labcorp for $210 million in cash.
- 02Management cites pressure on HCT reimbursement and financial stability.
- 03The Ascend initiative aims to improve productivity, efficiency and cost structure.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets